Aarvik Therapeutics, Inc.

ArriVent Biopharma, Inc. launched the second biopharmaceutical company initial public offering of 2024, a day after CG Oncology, Inc. became the first drug developer to go public in the US this yea

Alzheimer’s disease is top of mind due to the millions of people in need of effective treatments and the rapid rise in the AD population globally – and because the first disease-modifying therapy has

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Roche/Genentech Bring In Cell Therapy C